This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Venlafaxine and hypertension

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • venlafaxine has been associated with reports of hypertension since its introduction - a meta-analysis of phase III trials (3,744 patients) revealed that diastolic hypertension was only seen more significantly in patients treated with doses of venlafaxine more than 300 mg per day (1). The rate of hypertension varied with respect to dose of venlafaxine:
    • 1.7% on doses less than 101 mg per day
    • 3.5% on doses 101-200 mg per day
    • 3.7% on doses 201-300 mg per day
    • 9.1% on doses over 300 mg per day
    • rate of hypertension in depressed patients taking placebo was 2.2%

  • in patients taking high dose venlafaxine, the mean increase diastolic blood pressure was 7-10 mmHg

  • in patients developing hypertension with venlafaxine a simple dose reduction may suffice to treat the hypertension (with subsequent careful monitoring of blood pressure) - if this measure is unsuccessfull or there is a recurrence of the depression then a different drug should be used

Reference:

  • Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3,744 depressed patients. J Clin Psychiatry 1998;59 (10):502-8.
  • Prescribers' Journal 2000; 40 (2):169-174.

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.